Alzheimer's Disease Therapeutics and Diagnostics Market Forecast 2014-2024 : Opportunities for Leading Companies

LONDON, Oct. 1, 2014 /PRNewswire/ -- Report Details

Alzheimer's medicine – your guide to technologies, trends and revenues
Where is the Alzheimer's disease treatment market heading? Visiongain's new report gives you revenue predictions for those drugs and diagnostic tests from 2014, helping you stay ahead.

Our 182-page report provides 131 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews trends and opportunities, and revenue predictions.

Forecasts from 2014-2024 and other analyses show you commercial prospects
Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter's Five Forces Analysis), company profiles and commercial developments. Read the full transcripts of three exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
- Dr. Simon Ridley, Head of Research, Alzheimer's Research UK
- David Hanlon, Director of Business Development and Strategic Collaborations, Quanterix
- Elizabeth Edgerly, PhD., Chief Program Officer, The Alzheimer's Association Northern California and Northern Nevada

Many opportunities exist for diagnosis and treatment of Alzheimer's. Our new study shows you the most promising and lucrative parts of that CNS market, helping you stay ahead

Discover sales predictions for the world market and submarkets

Along with revenue prediction of the overall world market, you see forecasts to 2024 for these two submarkets:
• Medicines for Alzheimer's disease
• Diagnostics for Alzheimer's (including biomarkers).

Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

See revenue forecasts for Alzheimer's disease drugs

How will leading drugs perform to 2024 at world level? Our study predicts individual revenues of three products:
• Namenda
• Aricept
• Exelon

And also three pipeline products:
• Solanezumab
• Gantenerumab
• MK-8931

There you discover how high sales can go. You see what's happening, understanding trends, challenges and opportunities.

Our analysis also breaks the main world forecast into geographical markets.

What are the prospects in the leading regions and countries?
Developments worldwide expand the market for diagnosing, treating and monitoring neurodegenerative disorders. Developed and developing national markets hold high potential from 2014.

In addition to analyses of the overall world market, you discover revenue forecasts for 11 leading national markets to 2024:
• US
• Japan
• Germany
• France
• UK
• Spain
• Italy
• Rest of Europe
• China
• Brazil
• Russia
• India
• Rest of the World

There you find potential. Large companies and specialty biopharma and diagnostics firms face many opportunities. Our study explains, assessing developments to help your work.

Leading companies and potential for market growth

Overall world revenue for Alzheimer's disease therapeutics and diagnostics will reach $7.0bn in 2014, our work forecasts. Our new study predicts the market will expand fast, especially beyond 2018. Disease-modifying therapies will transform that market. New drugs hold great potential from 2018 to 2024, given the prevalence of Alzheimer's and needs for more-effective treatments.

Our work shows you what organisation hold greatest potential. See profiles of 14 leading companies, including these:
• Pfizer
• Eisai
• Forest Laboratories
• Lundbeck
• Daiichi Sankyo
• Novartis
• TauRx Therapeutics
• Transtech Pharma
• Eli Lilly
• Amarantus BioScience Holdings, Inc
• Piramal Enterprises
• GE Healthcare
• Navidea
• Diagenic

In general, a company profile gives you the following information:
• Revenue forecasts for Alzheimer's disease drugs from 2014 to 2024
• Discussion of a company's activities and outlook
• Recent financial results
• Assessment of recent developments – mergers and acquisitions (M&A), new products, collaborations, including alliances, partnerships and joint ventures.

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What affects producers of those diagnostic tests and medicines?
Our report discusses issues and events affecting that industry and market from 2014, including these:
• Research and development (R&D) – drugs, diagnostic tests, and related technologies
• Disease prevalence – expanding patient populations
• Disease-modifying drugs and obstacles to cures
• Regulatory guidelines – changes and opportunities.

The study also discusses other aspects of diagnosing and treating Alzheimer's:
• Needs for Alzheimer's treatments
• Drugs and related technologies to transform the market
• Biomarkers and diagnostic imaging technologies, including structural, functional, and molecular imaging
• Diagnostic tests in development
• Deep brain stimulation (functional neuromodulation)
• Intellectual property (IP), licensing agreements and partnerships.

That way, you explore the industry's strengths, weaknesses, opportunities, and threats. You also analyse it through Porter's five forces.

See, then, what the future holds.

How the Alzheimer's Disease Therapeutics and Diagnostics Market Forecast 2014-2024: Opportunities for Leading Companies report helps you

In summary, our 182-page report gives you the following knowledge:
• Revenue forecast to 2024 for the world Alzheimer's disease therapeutics and diagnostics market and 2 submarkets - Discover the industry's prospects, finding promising places for investment and revenues.
• Revenue forecasts to 2024 for the leading 11 national markets – US, Japan, Germany, France, UK, Italy, Spain, Rest of Europe, Brazil, Russia, China, India, and Rest of the World
• Assessment of 14 leading companies – hear about products, results and strategies including revenue forecasts for Alzheimer's disease drugs to 2024
• Predicted revenues for 3 Alzheimer's disease drugs in the market and 3 promising drugs in the pipeline to 2024 – see potentials of top products and promising products in development.
• Review of R&D pipelines – investigate developmental trends and progress
• Discussion of what stimulates and restrains companies in the market
• Prospects for established firms and those seeking to enter the market
• View opinions from our survey, seeing interviews with three leading authorities

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Download the full report: https://www.reportbuyer.com/product/2390350/

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer